Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.041
Neutral
RSI(14)
60.443
Neutral
STOCH(KDJ)(9,3,3)
46.629
Sell
ATR(14)
1.597
Low Volatility
CCI(14)
-28.362
Neutral
Williams %R
48.110
Neutral
TRIX(12,20)
6.074
Buy
StochRSI(14)
0.000
Oversold
Edesa Biotech Inc
EDSA6.570USD
-0.450-6.41%
Close 03/25, 16:00（ET）Quotes delayed by 15 min
589.03KMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Edesa Biotech Inc
Currency: USD Updated: 2026-03-25Key Insights
Edesa Biotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 92 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Edesa Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Edesa Biotech Inc Highlights
StrengthsRisks
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Undervalued
The company’s latest PE is -6.17, at a low 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 37.60K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
+41.39%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-25The current financial score of Edesa Biotech Inc is 6.94, ranking 165 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.28
Operational Efficiency
2.66
Growth Potential
6.75
Shareholder Returns
7.03
Edesa Biotech Inc's Company Valuation
Currency: USD Updated: 2026-03-25The current valuation score of Edesa Biotech Inc is 6.60, ranking 246 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.17, which is -97.99% below the recent high of -0.12 and -18.42% above the recent low of -7.31.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 92/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-25The current earnings forecast score of Edesa Biotech Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 19.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
+41.39%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Edesa Biotech Inc
EDSA
2
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-25The current price momentum score of Edesa Biotech Inc is 9.03, ranking 28 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.16 and the support level at 2.19, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
7.190
Sell
MA10
6.810
Sell
MA20
5.677
Buy
MA50
3.004
Buy
MA100
2.321
Buy
MA200
2.318
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-25Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-03-25The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Edesa Biotech Inc is 2.19, ranking 241 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is -0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
-0.97
VaR
+7.41%
240-Day Maximum Drawdown
+72.22%
240-Day Volatility
+127.98%
Return
Best Daily Return
60 days
+90.79%
120 days
+90.79%
5 years
+102.73%
Worst Daily Return
60 days
-15.46%
120 days
-17.87%
5 years
-42.07%
Sharpe Ratio
60 days
+3.27
120 days
+1.72
5 years
+0.23
Risk Assessment
Maximum Drawdown
240 days
+72.22%
3 years
+88.46%
5 years
+99.04%
Return-to-Drawdown Ratio
240 days
+2.70
3 years
-0.02
5 years
-0.17
Skewness
240 days
+5.77
3 years
+6.10
5 years
+5.75
Volatility
Realised Volatility
240 days
+127.98%
5 years
+119.63%
Standardised True Range
240 days
+3.64%
5 years
+13.58%
Downside Risk-Adjusted Return
120 days
+638.95%
240 days
+638.95%
Maximum Daily Upside Volatility
60 days
+373.81%
Maximum Daily Downside Volatility
60 days
+94.09%
Liquidity
Average Turnover Rate
60 days
+0.34%
120 days
+0.38%
5 years
--
Turnover Deviation
20 days
-96.44%
60 days
-95.93%
120 days
-95.47%
Peer Comparison
Biotechnology & Medical Research
Edesa Biotech Inc
EDSA
6.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AnaptysBio Inc
ANAB
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
